Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A national cohort (Comunica-TTD working group).

Federico Longo,Oscar Alfredo Castillo Trujillo,Juan José Serrano Domingo,Roberto Martín Huertas,Elena Corral de la Fuente,Alberto San Juan del Moral,Jaime Portela,Juana María Cano,Pablo Reguera Puertas,Mercedes Rodríguez-Garrote,Marta Izquierdo-Manuel,Paula Jiménez-Fonseca,Alfredo Carrato,Enrique Aranda

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A national cohort (Comunica-TTD working group).

2019

Federico Longo
Oscar Alfredo Castillo Trujillo
Juan José Serrano Domingo
Roberto Martín Huertas
Elena Corral de la Fuente
Alberto San Juan del Moral
Jaime Portela
Juana María Cano
Pablo Reguera Puertas
Mercedes Rodríguez-Garrote
Marta Izquierdo-Manuel
Paula Jiménez-Fonseca
Alfredo Carrato
Enrique Aranda

e15707Background: Advanced pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with a five-year overall survival (OS) of less than 5%. Folfirinox and Nab-Paclitaxel plus Gemcitabine ...

Keywords:

Nab-paclitaxel
Cohort
Pathology
FOLFIRINOX
Oncology
Gemcitabine
Medicine
Chemotherapy
Adenocarcinoma
Internal medicine
first line chemotherapy
pancreatic ductal adenocarcinoma
national cohort
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations